Glenmark Pharmaceuticals Inc, USA has announced the commercial launch of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial, further expanding the company’s portfolio of institutional medicines available to healthcare providers across the United States. The newly launched product is bioequivalent and therapeutically equivalent to the reference listed drug ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL), approved under NDA 204630. The introduction of the product reflects Glenmark’s continued focus on providing high-quality, cost-effective treatment options that support hospitals, healthcare systems, and patients nationwide.
Methylene Blue Injection is an important pharmaceutical product used within institutional healthcare settings, where reliable access to essential medications remains a priority. By adding this product to its growing portfolio, Glenmark aims to strengthen supply continuity while offering healthcare institutions an additional trusted sourcing option.
According to IQVIA sales data for the 12-month period ending April 2026, the US market for ProvayBlue Injection, 50 mg/10 mL (5 mg/mL), generated annual sales of approximately $19 million. The market opportunity highlights the ongoing demand for therapeutically equivalent alternatives that can help healthcare providers manage costs while maintaining clinical standards.
Commenting on the launch, Marc Kikuchi, President and Business Head, North America, emphasized the company’s commitment to supporting healthcare providers with dependable pharmaceutical solutions. He noted that the addition of Methylene Blue Injection USP aligns with Glenmark’s strategy of expanding access to affordable medicines while addressing the evolving needs of healthcare institutions throughout the country.
The launch represents another milestone in Glenmark’s broader effort to enhance its institutional product offerings and strengthen its presence in the US pharmaceutical market. The company continues to invest in the development and commercialization of products that improve accessibility and support patient care across multiple therapeutic categories.
Glenmark Pharmaceuticals Inc, USA remains focused on delivering quality-driven pharmaceutical products through a combination of scientific expertise, regulatory compliance, and customer-centric service. By continuously broadening its product portfolio, the company seeks to provide healthcare professionals with reliable treatment options that contribute to improved patient outcomes and operational efficiency within healthcare facilities. With the introduction of Methylene Blue Injection USP, Glenmark reinforces its commitment to expanding access to essential medicines and supporting the healthcare community with dependable, affordable pharmaceutical solutions across the United States